var data={"title":"Fluconazole: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluconazole: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6203?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">see &quot;Fluconazole: Drug information&quot;</a> and <a href=\"topic.htm?path=fluconazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluconazole: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171677\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Diflucan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171678\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACT Fluconazole;</li>\n      <li>Apo-Fluconazole;</li>\n      <li>CanesOral;</li>\n      <li>CO Fluconazole;</li>\n      <li>Diflucan;</li>\n      <li>Diflucan injection;</li>\n      <li>Diflucan One;</li>\n      <li>Diflucan PWS;</li>\n      <li>Dom-Fluconazole;</li>\n      <li>Fluconazole Injection;</li>\n      <li>Fluconazole Injection SDZ;</li>\n      <li>Fluconazole Omega;</li>\n      <li>Monicure;</li>\n      <li>Mylan-Fluconazole;</li>\n      <li>Novo-Fluconazole;</li>\n      <li>PHL-Fluconazole;</li>\n      <li>PMS-Fluconazole;</li>\n      <li>PRO-Fluconazole;</li>\n      <li>Riva-Fluconazole;</li>\n      <li>Taro-Fluconazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047385\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent, Systemic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442534\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Daily dose of fluconazole is the same for oral and IV administration; unless otherwise specified, either dosage form may be used: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis:</b> IV, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\"> Invasive (systemic):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis:</i> Dosing based on IDSA guidelines and a pharmacokinetic simulation. Duration should be guided by presence of risk factors. Optimal criteria and duration of fluconazole prophylaxis need further defined(Healy, 2009). </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GA &lt;30 weeks: Consider for neonates with a birth weight &lt;1000 g who are in a nursery with a high rate of invasive candidiasis. </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Age at initiation of therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">PNA &lt;7 days: IV: 3 mg/kg/dose or 6 mg/kg/dose twice weekly; in ELBW, therapy initiation recommended during first 48-72 hours of life by the IV route and continued for 4-6 weeks or until IV access no longer required for care of the neonate (Pappas, 2009; <i>Red Book</i>, 2012). <b>Note:</b> Dose selection may be directed by NICU-specific <i>Candida</i> sp. susceptibility (ie, use lower dose for an organism with an MIC &le;2 mcg/mL; neither dose has been studied for organisms with an MIC &gt;4 mcg/mL) (Pappas, 2009; Wade, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">PNA &ge;7-42 days: 3 mg/kg/dose once daily or 6 mg/kg/dose every 72 hours (Wade, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">PNA &gt;42 days: 6 mg/kg/dose every 48 hours (Wade, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GA 30-40 weeks: 6 mg/kg/dose every 48 hours (Wade, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Systemic candidiasis, invasive disease: 12 mg/kg/dose once daily for 21 days; gestational age not specified (Pappas, 2009). Others have recommended a loading dose of 25 mg/kg, followed by 12 mg/kg once daily; an evaluation of this dosing in five neonates (GA: 35-38 weeks; PNA: 16 days) showed all subjects reached target trough concentrations (&gt;8 mcg/mL) within 24 hours (Piper, 2011; Wade, 2008; Wade, 2009). Some experts have suggested 12 mg/kg/dose every 48 hours for PNA &lt;8 days. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral (thrush) (Pappas, 2009): Term neonate:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">PNA &le;14 days: Initial: 6 mg/kg/dose followed by 3 mg/kg/dose every 24-72 hours for 7-14 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">PNA &gt;14 days: Initial: 6 mg/kg/dose followed by 3 mg/kg/dose once daily for 7-14 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Esophageal disease (Pappas, 2009): Term neonate: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">PNA &le;14 days: Initial: 6 mg/kg/dose followed by 3 mg/kg/dose every 24-72 hours for a minimum of 14-21 days; duration of therapy based upon clinical response; some suggest to continue for 2 weeks after clinical resolution with a minimum of at least 3 weeks of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">PNA &gt;14 days: Initial: 6 mg/kg/dose followed by 3 mg/kg/dose once daily for a minimum of 14-21 days; in some cases, doses up to 12 mg/kg may be required; duration of therapy based upon clinical response; continue for 2 weeks after clinical resolution with a minimum of at least 3 weeks of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cryptococcal, CNS disease (meningitis):</b> IV, Oral: PNA &gt;14 days: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute treatment:</i> 12 mg/kg/dose followed by 6-12 mg/kg/day for 10-12 weeks after CSF culture becomes negative </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prevention of relapse:</i> 6 mg/kg/dose once daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no specific neonatal dosage adjustments provided in the manufacturer's labeling; some experts have used the following indication-specific dosing (Wade, 2009): Candidiasis, prophylaxis: IV, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">S<sub>cr</sub> &ge;1.3 mg/dL: 6 mg/kg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">S<sub>cr</sub> &le;1 mg/dL: Standard dosing </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047378\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">see &quot;Fluconazole: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants and Children: <b>Note:</b> Daily dose of fluconazole is the same for oral and IV administration; unless otherwise specified, either dosage form may be used: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> IV, Oral: Initial: 6 to 12 mg/kg/dose, followed by 3 to 12 mg/kg/dose once daily; maximum daily dose: 600 mg/<b>day</b>; duration and dosage depends on severity of infection </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis:</b> IV, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis regimens: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Chemotherapy-induced neutropenia (including stem cell transplantation): 6 mg/kg/dose once daily during induction chemotherapy and period of neutropenia risk; maximum daily dose: 400 mg/<b>day</b> (Pappas 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postsolid organ transplant: 6 mg/kg/dose once daily for 14 days; maximum daily dose: 400 mg/<b>day</b> (Pappas 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment and suppression regimens:   </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Esophageal infection:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Non-HIV-exposed/-positive: <i>Treatment:</i> 6 mg/kg/dose on Day 1, followed by 3 mg/kg/dose once daily for at least 21 days and at least 2 weeks following symptom resolution. In some cases, higher doses (up to 12 mg/kg/<b>day</b>) may be used; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive (CDC 2009): </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>Treatment:</i> 6 mg/kg/dose on Day 1, followed by 3 to 6 mg/kg/dose once daily for 4 to 21 days; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>Relapse suppression:</i> 3 to 6 mg/kg/dose once daily; maximum daily dose: 200 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oropharyngeal infection:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Non-HIV-exposed/-positive: <i>Treatment:</i> 6 mg/kg/dose on Day 1, followed by 3 mg/kg/dose once daily for at least 14 days; maximum daily dose: Day 1: 200 mg/<b>day</b>; subsequent days: 100 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\"> HIV-exposed/-positive: <i>Treatment:</i> 3 to 6 mg/kg/dose once daily for 7 to 14 days; maximum daily dose: 400 mg/<b>day</b> (CDC, 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Systemic infection (invasive disease):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Non-HIV-exposed/-positive (neutropenic or non-neutropenic patients; reserve use for stable patients only): <i>Treatment:</i> 12 mg/kg/dose on Day 1 (maximum dose: 800 mg), followed by 12 mg/kg/dose once daily or 6 mg/kg/dose twice daily; maximum daily dose: 600 mg/<b>day</b>; treatment duration: 2 weeks after clearance from blood and symptom resolution (Filioti 2007; Pappas 2009; Zaoutis 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive: <i>Treatment:</i> 5 to 6 mg/kg/dose twice daily for minimum of 4 weeks; maximum daily dose: 600 mg/<b>day</b>; reserve for documented <i>C. albicans</i> or other susceptible species (CDC 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter (peritoneal dialysis); exit-site or tunnel infection:</b> Oral: 6 mg/kg/dose every 24 to 48 hours; maximum dose: 400 mg/dose (Warady [ISPD] 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coccidioidomycosis, meningeal infection, or in a stable patient with diffuse pulmonary or disseminated disease (HIV-exposed/-positive)</b> (CDC 2009): IV, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i> 5 to 6 mg/kg/dose twice daily; maximum daily dose: 800 mg/<b>day</b>, followed by chronic suppressive therapy </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> Relapse suppression:</i> 6 mg/kg/dose once daily; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryptococcal infection:</b> IV, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CNS disease:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Acute therapy: </i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Manufacturer's labeling: 12 mg/kg/dose on Day 1, followed by 6 mg/kg/dose once daily; in some cases, doses as high as 12 mg/kg/day once daily may be required dependent upon patient's response to therapy; treatment duration 10 to 12 weeks after CSF becomes culture negative; maximum daily dose: 800 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Alternate dosing: Consolidation phase: Oral: 5 to 6 mg/kg/dose <b>twice</b> daily; treatment duration: 8 weeks followed by maintenance therapy; maximum daily dose: 800 mg/<b>day</b> (Perfect 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Maintenance therapy:</i> 6 mg/kg/dose once daily for 6 to 12 months; maximum daily dose: 200 mg/<b>day</b> (Perfect 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-exposed/-positive: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Acute therapy, induction:</i> 12 mg/kg /dose on Day 1, followed by 6 to 12 mg/kg/dose once daily; maximum daily dose: 800 mg/<b>day</b>; in combination with flucytosine for at least 2 weeks until significant clinical improvement and negative CSF cultures then begin consolidation therapy; reserve as alternate therapy when amphotericin (including lipid-based products) is not tolerated (CDC 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Consolidation therapy:</i> 12 mg/kg/dose on Day 1, followed by 6-12 mg/kg/dose once daily for a minimum of 8 weeks; maximum daily dose: 800 mg/<b>day</b>; <b>Note:</b> CSF cultures should be negative prior to initiating consolidation therapy (CDC 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Relapse suppression:</i> 6 mg/kg/dose once daily; maximum daily dose: 200 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Localized (non-CNS), disseminated, or pulmonary disease:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild-moderate pulmonary disease or localized infection: <i>Treatment:</i> 6 mg/kg once daily; maximum daily dose: 400 mg/<b>day</b>; a treatment duration of 6 to 12 months has been used in organ transplant recipients (Perfect 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Severe pulmonary disease, or disseminated infection; treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>Acute therapy:</i> 12 mg/kg/dose on Day 1, followed by 6 mg/kg/dose once daily; in some cases, doses as high as 12 mg/kg/dose once daily may be used dependent upon patient's response to therapy; treatment duration 10 to 12 weeks; maximum daily dose: 800 mg/<b>day</b> (Perfect 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>Maintenance therapy:</i> 6 mg/kg/dose once daily for 6 to 12 months; maximum daily dose: 200 mg/<b>day</b> (Perfect 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-exposed/-positive (CDC 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Treatment:</i> 12 mg/kg/dose on Day 1, followed by 6 to 12 mg/kg/dose once daily; maximum daily dose: 600 mg/<b>day</b>; treatment duration variable and dependent upon infection site, severity, and clinical response; chronic suppressive therapy should be initiated upon treatment completion </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Relapse suppression:</i> 6 mg/kg/dose once daily; maximum daily dose: 200 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Histoplasmosis; relapse prevention (HIV-exposed/-positive):</b> IV, Oral: 3 to 6 mg/kg/dose once daily; maximum daily dose: 200 mg/<b>day</b> (CDC 2009). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis):</b> (Warady [ISPD] 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis during antibiotic therapy:</i> IV, Oral: 3 to 6 mg/kg/dose every 24 to 48 hours; maximum dose: 200 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i> Intraperitoneal, IV, Oral: 6 to 12 mg/kg/dose every 24 to 48 hours; maximum dose: 400 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> IV: 6 mg/kg as a single dose 1 to 2 hours prior to procedure; maximum dose: 400 mg (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>General dosing, susceptible infection:</b> IV, Oral: Initial: 6 to 12 mg/kg/dose followed by 3 to 12 mg/kg/dose once daily; maximum daily dose: 600 mg/<b>day</b>; duration and dosage depend on severity of infection </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Blastomycosis, CNS disease (independent of HIV status):</b>  Oral: <i>Step-down therapy:</i> 800 mg once daily; initiate after 4 to 6 weeks of amphotericin therapy and continue for at least 12 months or until resolution of CNS abnormalities has been recommended in adult patients (Chapman 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Candidiasis:</b> IV, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">Prophylaxis regimens:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Chemotherapy-induced neutropenia (including stem cell transplantation): 6 mg/kg/dose once daily during induction chemotherapy and period of neutropenia risk; maximum daily dose: 400 mg/<b>day</b> (Pappas 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Postsolid organ transplant: 6 mg/kg/dose once daily for 14 days; maximum daily dose: 400 mg/<b>day</b> (Pappas 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">Treatment and suppression regimens:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Esophageal infection:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">Non-HIV-exposed/-positive: <i>Treatment:</i> 6 mg/kg/dose on Day 1, followed by 3 mg/kg/dose once daily for at least 21 days and at least 2 weeks following symptom resolutions. In some cases, higher doses (up to 12 mg/kg/<b>day</b>) may be used; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">HIV-exposed/-positive (DHHS 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">\n      <i>Treatment:</i> 100 mg once daily for 14 to 21 days; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">\n      <i>Relapse suppression:</i> 100 to 200 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Oropharyngeal infection:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">Non-HIV-exposed/-positive: <i>Treatment:</i> 6 mg/kg/dose on Day 1, followed by 3 mg/kg/dose once daily for at least 14 days; maximum daily dose: Day 1: 200 mg/<b>day</b>; subsequent doses: 100 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">HIV-exposed/-positive (DHHS 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">\n      <i>Treatment:</i> Oral: 100 mg once daily for 7 to 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">\n      <i>Relapse suppression:</i> Oral: 100 mg once daily or 3 times weekly </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Systemic infection (invasive disease): Neutropenic or non-neutropenic patients (non-HIV-exposed/-positive; reserve use for stable patients only): <i>Treatment:</i> 12 mg/kg/dose on Day 1 (maximum dose: 800 mg) followed by 12 mg/kg/dose once daily or 6 mg/kg/dose twice daily (maximum daily dose: 600 mg/<b>day</b>); treatment duration: 2 weeks after clearance from blood and symptom resolution (Fioliti 2007; Pappas 2009; Zaoutis 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Vulvovaginal infection:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">Uncomplicated (independent of HIV status): <i>Treatment:</i> Oral: 150 mg single dose (CDC 2010; CDC 2013) </p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">Complicated (severe, recurrent) (HIV-exposed/-positive) (DHHS 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">\n      <i>Treatment:</i> 100 to 200 mg once daily for at least 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">\n      <i>Relapse suppression:</i> Oral: 150 mg/dose once weekly </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter (peritoneal dialysis); exit-site or tunnel infection:</b> Oral: 6 mg/kg/dose every 24 to 48 hours; maximum dose: 400 mg/dose (Warady [ISPD] 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coccidioidomycosis:</b> IV, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-CNS disease:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-HIV-exposed/-positive: <i>Treatment:</i> 400 to 800 mg once daily; for severe disseminated extrapulmonary infection, doses up to 2,000 mg/day have been used; total therapy duration (treatment and maintenance) dependent upon site of infection; for pneumonia (diffuse) at least 12 months (if patient immunosuppressed, consider additional suppression therapy); for other disseminated (nonpulmonary infections), treatment duration based upon clinical response and may extend longer than 12 months (Galgiani 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-exposed/-positive (CDC 2013): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Prevention, first episode:</i> Oral: 400 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Mild infection or focal pneumonia: 400 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Severe infection (eg, diffuse pulmonary infection or extrathoracic disseminated disease): 400 mg once daily in combination with amphotericin; continue fluconazole after amphotericin stopped following clinical improvement</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Chronic suppressive therapy:</i> Oral: 400 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningeal infection:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-HIV-exposed/-positive: <i>Treatment:</i> 400 to 1000 mg once daily, continue indefinitely (Galgiani 2005) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-exposed/-positive (DHHS 2013): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Treatment:</i> 400 to 800 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Suppression:</i> Oral: 400 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Cryptococcal infection:</b> IV, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">CNS disease: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Non-HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">\n      <i>Treatment:</i> Acute therapy: 12 mg/kg/dose on Day 1, followed by 6 mg/kg/dose once daily; in some cases doses as high as 12 mg/kg/dose once daily may be used dependent upon patient's response to therapy; treatment duration 10 to 12 weeks; maximum daily dose: 800 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">\n      <i>Consolidation therapy:</i> Oral: 5 to 6 mg/kg/dose <b>twice</b> daily for 8 weeks; maximum daily dose: 800 mg/<b>day</b> (Perfect 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">\n      <i>Maintenance therapy:</i> Oral: 6 mg/kg/dose once daily; maximum daily dose: 200 mg/<b>day</b> (Perfect 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">HIV-exposed/-positive (DHHS 2013): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">\n      <i>Induction:</i> Continue therapy for at least 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">Combination therapy: 800 mg once daily with amphotericin or liposomal amphotericin; if patient unable to tolerate amphotericin (or lipid product formulations) may use 400 to 800 mg/dose once daily with flucytosine</p>\n    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">Monotherapy: 1,200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">\n      <i>Consolidation therapy:</i> 400 mg once daily for 8 weeks; begin after at least 2 weeks of induction therapy (ie, significant clinical improvement and negative CSF cultures)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">\n      <i>Maintenance therapy:</i> Oral: 200 mg once daily for at least 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">Localized (non-CNS), disseminated, or pulmonary disease:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Non-HIV-exposed/-positive: Cryptococcal pneumonia: Oral: <i>Treatment:</i> 6 to 12 mg/kg/dose once daily for 6 to 12 months; maximum daily dose: 800 mg/<b>day</b> (Perfect 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">HIV-exposed/-positive (DHHS 2013): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">Diffuse pulmonary disease or extrapulmonary disease: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">\n      <i>Induction:</i> Continue therapy for at least 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:14em;margin-top:0em;\">Combination therapy: 800 mg once daily with amphotericin or liposomal amphotericin; if patient unable to tolerate amphotericin (or lipid product formulations) may use 400 to 800 mg/dose once daily with flucytosine </p>\n    <p style=\"text-indent:-2em;margin-left:14em;margin-top:0em;\">Monotherapy: 1200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">\n      <i>Consolidation therapy:</i> Oral: 400 mg once daily for 8 weeks; begin after at least 2 weeks of induction therapy (ie, significant clinical improvement and negative CSF cultures)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;margin-top:0em;\">\n      <i>Maintenance therapy:</i> Oral: 200 mg once daily for at least 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">Focal pulmonary infiltrates or mild-moderate symptoms: Oral: 400 mg once daily for 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Histoplasmosis:</b> IV, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HIV-exposed/-positive (Wheat 2007): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Treatment:</i> 200 to 800 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Maintenance (CNS disease):</i> Following 8 weeks of amphotericin B, fluconazole 200 to 400 mg once daily for 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-positive (DHHS 2013): Duration of therapy for induction and maintenance at least 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Treatment, less severe disease:</i> Oral: 800 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Maintenance (severe disseminated or CNS disease):</i> Oral: 800 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Suppression, long-term (severe disseminated or CNS disease):</i> Oral: 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Penicilliosis; prevention first episode (HIV-exposed/-positive):</b> Oral: 400 mg once weekly (DHHS 2013) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis):</b> (Warady [ISPD] 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis</i>: IV, Oral: 3 to 6 mg/kg/dose every 24 to 48 hours; maximum dose: 200 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment: </i> Intraperitoneal, IV, Oral: 6 to 12 mg/kg/dose every 24 to 48 hours; maximum dose: 400 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> IV: 6 mg/kg as a single dose 1 to 2 hours prior to procedure; maximum dose: 400 mg (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Adult: <b>Usual dosage range:</b> 150 mg once <b>or</b> 200 to 800 mg/day; duration and dosage depend on severity of infection </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Infants, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">No adjustment for vaginal candidiasis single-dose therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">For multiple dosing, administer usual load then adjust daily doses as follows; based upon Schwartz calculations: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">CrCl &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">CrCl 10-50 mL/minute/1.73 m<sup>2</sup> (no dialysis): Administer 50% of recommended dose at the normal interval.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">CrCl &le;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of recommended dose every 48 hours (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Intermittent hemodialysis: Dialyzable (50%): May administer 100% of daily dose (according to indication) after each dialysis session; others have suggested the following: Administer 50% of dose every 48 hours; on dialysis days administer dose after dialysis session (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Peritoneal dialysis: Administer 50% of recommended dose every 48 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Continuous renal replacement (CRRT): 6 mg/kg/dose every 24 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">No adjustment for vaginal candidiasis single-dose therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">For multiple dosing, administer usual load then adjust daily doses as follows: Administer loading dose of 50 to 400 mg, then adjust daily doses as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">CrCl &le;50 mL/minute (no dialysis): Administer 50% of recommended dose daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\"> Intermittent hemodialysis (IHD): Dialyzable (50%): May administer 100% of daily dose (according to indication) after each dialysis session. Alternatively, doses of 200 to 400 mg every 48 to 72 hours or 100 to 200 mg every 24 hours have been recommended (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">CVVH: Loading dose of 400 to 800 mg followed by 200 to 400 mg every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">CVVHD/CVVHDF: Loading dose of 400 to 800 mg followed by 400 to 800 mg every 24 hours (CVVHD or CVVHDF) or 800 mg every 24 hours (CVVHDF) </p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">\n      <b>Note:</b> Higher maintenance doses of 400 mg every 24 hours (CVVH), 800 mg every 24 hours (CVVHD), and 500 to 600 mg every 12 hours (CVVHDF) may be considered when treating resistant organisms and/or when employing combined ultrafiltration and dialysis flow rates of &ge;2 L/hour for CVVHD/CVVHDF (Heintz 2009; Trotman 2005). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171652\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg (50 mL); 200 mg (100 mL); 400 mg (200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg (100 mL); 400 mg (200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diflucan: 10 mg/mL (35 mL); 40 mg/mL (35 mL) [orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (35 mL); 40 mg/mL (35 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diflucan: 50 mg, 100 mg, 150 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 100 mg, 150 mg, 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171637\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047389\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer without regard to meals; shake suspension well before use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Do not use if cloudy or precipitated. Administered by IV infusion over approximately 1 to 2 hours at a rate not to exceed 200 mg/hour; in  pediatric clinical trials, doses up to 8 to 10 mg/kg were infused over 2 hours (Driessen 1996; Lee 1992)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132520\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV compounding, double gloves, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) are recommended. Double gloving and a gown are required during IV administration (NIOSH 2016). Premixed solutions may be excluded from some hazardous drug handling requirements. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171672\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet: Store at &lt;30&deg;C (86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder for oral suspension: Store dry powder at &lt;30&deg;C (86&deg;F). Following reconstitution, store at 5&deg;C to 30&deg;C (41&deg;F to 86&deg;F). Discard unused portion after 2 weeks. Do not freeze. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Store injection in glass at 5&deg;C to 30&deg;C (41&deg;F to 86&deg;F). Store injection in plastic flexible containers with overwrap at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Do not freeze. Do not unwrap unit until ready for use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047388\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of candidiasis (vaginal, oropharyngeal, esophageal, urinary tract infections, peritonitis, pneumonia, and systemic infections); cryptococcal meningitis; antifungal prophylaxis in allogeneic bone marrow transplant recipients (All indications: FDA approved in all ages). Has also been used as an alternative to amphotericin B in patients with preexisting renal impairment or when requiring concomitant therapy with other potentially nephrotoxic drugs;   prophylaxis and treatment of peritonitis and treatment of exit site and tunnel infections in patients with peritoneal dialysis catheters; fluconazole is more active against <i>C. albicans</i> than other candidal strains like <i>C. parapsilosis</i>, <i>C. glabrata</i>, and <i>C. tropicalis</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171739\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fluconazole may be confused with flecainide, FLUoxetine, furosemide, itraconazole, voriconazole</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diflucan may be confused with diclofenac, Diprivan, disulfiram</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Canesten (oral capsules) [Great Britain] may be confused with Canesten brand name for clotrimazole (various dosage forms) [multiple international markets]; Cenestin brand name estrogens (conjugated A/synthetic) [US, Canada] </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171736\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, dysgeusia, dyspepsia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatitis, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute generalized exanthematous pustulosis, agranulocytosis, alopecia, anaphylaxis, angioedema, cholestasis, diaphoresis, drowsiness, fatigue, fever, fixed drug eruption, hepatic failure, hypercholesterolemia, hypertriglyceridemia, hypokalemia, insomnia, leukopenia, malaise, myalgia, neutropenia, paresthesia, prolonged Q-T interval on ECG, seizure, Stevens-Johnson syndrome, thrombocytopenia, torsades de pointes, toxic epidermal necrolysis, tremor, vertigo, weakness, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171659\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to fluconazole or any component of the formulation (cross-reaction with other azole antifungal agents may occur, but has not been established; use caution); coadministration of terfenadine in adult patients receiving multiple doses of 400 mg or higher or with CYP3A4 substrates which may lead to QTc prolongation (eg, astemizole, cisapride, erythromycin, pimozide, or quinidine) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171641\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmias: Cases of QTc prolongation and torsade de pointes associated with fluconazole use have been reported (usually high dose or in combination with agents known to prolong the QT interval); use caution in patients with concomitant medications or conditions which are arrhythmogenic. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: May occasionally cause dizziness or seizures; use caution driving or operating machinery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: Serious (and sometimes fatal) hepatic toxicity (eg, hepatitis, cholestasis, fulminant hepatic failure) has been observed. Monitor patients who develop abnormal liver function tests for the development of more severe hepatic injury; discontinue fluconazole if signs and symptoms consistent with liver disease develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Anaphylaxis has been reported rarely; use with caution in patients with hypersensitivity to other azoles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin reactions: Rare exfoliative skin disorders have been observed; fatal outcomes have been reported in patients with serious concomitant diseases. Monitor patients with deep seated fungal infections closely for rash development and discontinue if lesions progress. In patients with superficial fungal infections who develop a rash attributable to fluconazole, treatment should also be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment:  Use with caution in patients with preexisting hepatic impairment; monitor liver function closely and  discontinue if symptoms consistent with liver disease develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sucrose: Oral suspension contains sucrose; avoid use in patients with fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171724\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C19 (strong), CYP2C9 (moderate), CYP3A4 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171646\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13303&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib.  Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfentanil: Fluconazole may increase the serum concentration of Alfentanil.  Management: Monitor for increased anesthetic and respiratory depressant effects if alfentanil is combined with fluconazole. Consider using lower initial doses of alfentanil or an alternative anesthetic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amitriptyline: May enhance the QTc-prolonging effect of Fluconazole. Fluconazole may increase the serum concentration of Amitriptyline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AmLODIPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Astemizole: Fluconazole may enhance the QTc-prolonging effect of Astemizole. Fluconazole may increase the serum concentration of Astemizole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: Fluconazole may increase the serum concentration of AtorvaSTATin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avanafil: Fluconazole may increase the serum concentration of Avanafil.  Management: Limit avanafil to a maximum dose of 50 mg per 24-hour period in any patient who is also receiving a moderate inhibitor of CYP3A4 such as fluconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended.  See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine.  Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor.  The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical).  Management: Per US prescribing information, avoid this combination. Canadian product labeling does not recommend strict avoidance. If combined, monitor for excessive glucocorticoid effects as budesonide exposure may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Busulfan. Isavuconazonium considerations are addressed in separate monographs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Fluconazole may increase the serum concentration of Calcium Channel Blockers. <b> Exceptions: </b>Clevidipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Fluconazole may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving moderate inhibitors of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride. Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Citalopram: Fluconazole may enhance the QTc-prolonging effect of Citalopram. Fluconazole may increase the serum concentration of Citalopram.  Management: If this combination cannot be avoided, consider a lower dose of citalopram and monitor closely for QTc prolongation and arrhythmias.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully consider the need for a strong CYP2C19 inhibitor in patients receiving clopidogrel. Monitor patients closely for evidence of a diminished response to clopidogrel.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib.  Management: Avoid the concomitant use of cobimetinib and moderate CYP3A4 inhibitors. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose to 20 mg daily.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Fluconazole may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Substrates (High risk with Inhibitors): CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inhibitors): CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Alitretinoin (Systemic); Praziquantel; Trabectedin; Vinorelbine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Fluconazole may enhance the anticoagulant effect of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.  Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Domperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP3A4 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan.  Management: The use of eletriptan within 72 hours of a moderate CYP3A4 inhibitor should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Use should be avoided under some circumstances.  See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Fluconazole may increase the serum concentration of Eplerenone.  Management: Reduce the starting dose of eplerenone to 25 mg/day; monitor patients closely for increased eplerenone effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): Fluconazole may enhance the QTc-prolonging effect of Erythromycin (Systemic). Fluconazole may increase the serum concentration of Erythromycin (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs. Etravirine may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole.  Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluvastatin: Fluconazole may increase the serum concentration of Fluvastatin.  Management: Limit fluvastatin maximum  adult dose to 20 mg twice daily, and monitor for toxic effects of fluvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities), during concomitant treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Fluconazole may increase the serum concentration of Fosphenytoin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.  Management: Extreme caution, with possibly increased monitoring of cardiac status (eg, ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HydrOXYzine.  Management: This combination is specifically contraindicated in some non-U.S. labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, decrease ibrutinib to 140 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions are required; consult full monograph content for specific age- and weight-based recommendations.  No dose adjustment is needed when using ivacaftor/lumacaftor with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Losartan: Fluconazole may decrease the serum concentration of Losartan. Specifically, fluconazole may decrease the serum concentration of E3174, the more potent active metabolite of losartan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: Fluconazole may increase the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: Lurasidone US labeling recommends reducing lurasidone dose by half with a moderate CYP3A4 inhibitor. Some non-US labeling recommends initiating lurasidone at 20 mg/day and limiting dose to 40 mg/day; avoid concurrent use of grapefruit products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Fluconazole may enhance the QTc-prolonging effect of Methadone. Fluconazole may increase the serum concentration of Methadone.  Management: Monitor patients closely for evidence of methadone toxicities, including but not limited to respiratory depression and QT-prolongation/torsades de pointes, if combined with fluconazole.  Methadone dose reductions may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: Fluconazole may increase the serum concentration of Nalmefene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nateglinide: Fluconazole may increase the serum concentration of Nateglinide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nevirapine: Fluconazole may increase the serum concentration of Nevirapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib.  Management: Avoid use of moderate CYP3A4 inhibitors in patients being treated with olaparib, if possible.  If such concurrent use cannot be avoided, the dose of olaparib should be reduced to 150 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: Fluconazole may increase the serum concentration of Ospemifene. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CYP3A4 Inhibitors (Moderate) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parecoxib: Fluconazole may increase the serum concentration of Parecoxib.  Management: Use the lowest possible dose of parecoxib in patients who are taking fluconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Fluconazole may increase the serum concentration of Phenytoin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may enhance the arrhythmogenic effect of Pimozide. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Pimozide. This increase in serum concentrations may lead to QTc interval prolongation and ventricular arrhythmias.  Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PredniSONE: Fluconazole may increase the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: Fluconazole may increase the serum concentration of Proton Pump Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramelteon: Fluconazole may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red Yeast Rice: Fluconazole may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected. Rifamycin Derivatives may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic).  Management: Avoid these combinations when possible.  Voriconazole and isavuconazonium are considered contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: Fluconazole may increase the serum concentration of Ruxolitinib.  Management: This combination should be avoided under some circumstances. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sildenafil: Fluconazole may increase the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: Fluconazole may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: Fluconazole may increase the serum concentration of Sirolimus.  Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Solifenacin. Applicable Isavuconazonium considerations are addressed in separate monographs.  Management: The manufacturer recommends not exceeding 5 mg daily of solifenacin during concomitant therapy with ketoconazole, or other potent CYP3A4 enzyme inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib.  Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible.  When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Fluconazole may increase the serum concentration of Sulfonylureas.  Management: Seek alternatives when possible.  If used together, monitor closely for increased effects of sulfonylureas if fluconazole is initiated/dose increased, or decreased effects if fluconazole is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of SUNItinib. Applicable Isavuconazonium considerations are addressed in separate monographs.  Management: Consider a reduced dose of sunitinib (minimum of 37.5 mg daily) during concomitant use. Concurrent use with itraconazole is not recommended per itraconazole labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Fluconazole may increase the serum concentration of Tacrolimus (Systemic).  Management: Monitor tacrolimus concentrations closely and adjust oral tacrolimus dose as necessary when concomitantly administered with fluconazole.  Reduced doses of tacrolimus will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tadalafil: Fluconazole may increase the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Telithromycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: Fluconazole may increase serum concentrations of the active metabolite(s) of Temsirolimus.  Management: Consider temsirolimus dose reductions or alternatives to fluconazole.  Monitor sirolimus concentrations in all patients receiving fluconazole or any systemic azole antifungal.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terfenadine: Fluconazole may enhance the QTc-prolonging effect of Terfenadine. Fluconazole may increase the serum concentration of Terfenadine.  Management: Concomitant use of fluconazole at doses of 400 mg/day or greater and terfenadine is contraindicated and should be avoided. If lower doses of fluconazole and terfenadine are combined, monitor patients for QT-prolongation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tezacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor.  Management: When combined with moderate CYP3A4 inhibitors, tezacaftor/ivacaftor (100 mg/150 mg) should be given in the morning, every other day. Ivacaftor (150 mg) alone should be given in the evening, every other day, on alternate days from tezacaftor/ivacaftor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Fluconazole may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: Fluconazole may increase the serum concentration of Tipranavir.  Management: Limit fluconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Fluconazole may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving moderate CYP3A4 inhibitors that strongly inhibit CYP2C19 (e.g., fluconazole, sitaxentan).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal.  Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When ulipristal is used as an emergency contraceptive, patients receiving this combination should be monitored for ulipristal toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vardenafil: Fluconazole may increase the serum concentration of Vardenafil.  Management: Limit vardenafil doses to a maximum of 5 mg per 24-hour period in patients receiving concurrent therapy with a moderate CYP3A4 inhibitor such as fluconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Fluconazole may increase the serum concentration of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: Fluconazole may increase the serum concentration of Voriconazole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Fluconazole may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone.  Management: The starting adult dose of zopiclone should not exceed 3.75 mg if combined with a moderate CYP3A4 inhibitor. Monitor patients for signs and symptoms of zopiclone toxicity if these agents are combined.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171648\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (single dose for vaginal candidiasis)/D (all other indications) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171662\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Following exposure during the first trimester, malformations have been noted in humans when fluconazole was used in higher doses (&ge;400 mg/day) over extended periods of time (eg, for the duration of pregnancy or intermittently throughout pregnancy). Abnormalities reported include brachycephaly, abnormal facies, abnormal calvarial development, cleft palate, femoral bowing, thin ribs and long bones, arthrogryposis, and congenital heart disease. Use of lower doses (150 mg as a single dose) does not suggest an increase risk to the fetus. However, available data are conflicting and further study is required to determine the risk to the fetus following the use of lower doses and/or shorter durations of therapy of oral fluconazole (FDA Safety Alert 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use of oral fluconazole for vaginal candidiasis is not recommended in pregnant women (HHS [OI adult 2017]; Workowski [CDC 2015]). Most azole antifungals, including fluconazole, are recommended to be avoided during the first trimester of pregnancy (IDSA [Pappas 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047384\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic liver function (AST, ALT, alkaline phosphatase), renal function tests, serum potassium, CBC with differential, and platelet count </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171640\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with fungal cytochrome P450 activity (lanosterol 14-&alpha;-demethylase), decreasing ergosterol synthesis (principal sterol in fungal cell membrane) and inhibiting cell membrane formation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171658\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed; food does not affect extent of absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~0.6 L/kg; widely throughout body with good penetration into CSF, eye, peritoneal fluid, sputum, skin, and urine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Relative diffusion blood into CSF: Adequate with or without inflammation (exceeds usual MICs)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF:blood level ratio: Normal meninges: 50% to 90%; Inflamed meninges: ~80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: 11% to 12%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: &gt;90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Normal renal function: ~30 hours (range: 20 to 50 hours); Elderly: 46.2 hours; Neonates (gestational age 26 to 29 weeks): 73.6 to 46.6 hours (decreases with increasing postnatal age); Pediatric patients 9 months to 15 years: 19.5 to 25 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13255706\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dosing equivalency suggested by the manufacturer's labeling: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients 3 mg/kg = Adults 100 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients 6 mg/kg = Adults 200 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients 12 mg/kg = Adults 400 mg \t</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171661\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fluconazole in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/100 mL (100 mL): $13.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/200 mL (200 mL): $15.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fluconazole in Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/50 mL 0.9% (50 mL): $10.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/100 mL 0.9% (100 mL): $11.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/200 mL 0.9% (200 mL): $6.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Diflucan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (35 mL): $193.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (35 mL): $670.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Fluconazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (35 mL): $35.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (35 mL): $129.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Diflucan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $863.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $1,356.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (12): $863.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $2,219.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Fluconazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $167.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $262.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (12): $167.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $429.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171665\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Afungil (MX);</li>\n      <li>Apicon (BD);</li>\n      <li>Asperlican (VN);</li>\n      <li>Avezol (MY);</li>\n      <li>Baten (DO, EC, GT, HN, PA, SV);</li>\n      <li>Biozole (MY);</li>\n      <li>Burnax (EC);</li>\n      <li>Canazole (BD);</li>\n      <li>Candid (BD);</li>\n      <li>Candifix (ES);</li>\n      <li>Candinil (LK);</li>\n      <li>Candizole (BE);</li>\n      <li>Canesoral (AU);</li>\n      <li>Cryptal (ID);</li>\n      <li>Diaflu (UA);</li>\n      <li>Diflazole (IE);</li>\n      <li>Diflazon (VN);</li>\n      <li>Diflucan (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CR, CZ, DE, DK, DO, EE, EG, ES, ET, FI, GB, GH, GM, GN, GT, GY, HK, HN, HR, HU, ID, IE, IS, IT, JM, JO, JP, KE, KR, KW, LB, LR, LT, LU, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, SV, TH, TN, TR, TT, TW, TZ, UG, VN, ZA, ZM, ZW);</li>\n      <li>DiflucanOne (AU);</li>\n      <li>Difluvid (MY, PH);</li>\n      <li>Difluzole (KR);</li>\n      <li>Difnazol (KR);</li>\n      <li>Dimycon (HR);</li>\n      <li>Dizole One (AU);</li>\n      <li>Dyflyuzol (UA);</li>\n      <li>Dyzolor (PH);</li>\n      <li>Eapacon (ET);</li>\n      <li>Exomax (HK);</li>\n      <li>FCZ Infusion (ID);</li>\n      <li>Flocan (KR);</li>\n      <li>FLU-D (TW);</li>\n      <li>Flucand (AE, BH, CY, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Flucanol (IL);</li>\n      <li>Flucazol (AE, BH, BR, CY, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Flucazole (NZ);</li>\n      <li>Flucogus (TW);</li>\n      <li>Flucol (IE);</li>\n      <li>Flucon (KR);</li>\n      <li>Flucona (KR);</li>\n      <li>Flucona-Denk (TZ);</li>\n      <li>Fluconal (BD);</li>\n      <li>Fluconaz (PH);</li>\n      <li>Flucoral (ID);</li>\n      <li>Flucoran (NZ);</li>\n      <li>Flucoxan (MX);</li>\n      <li>Flucozal (BR, LK, MT, PK);</li>\n      <li>Fludicon (HK);</li>\n      <li>Fludizol (TH);</li>\n      <li>Fluken (ZW);</li>\n      <li>Flumax (KR);</li>\n      <li>Flumyc (ZW);</li>\n      <li>Flunazol (CY);</li>\n      <li>Flunazole (TW);</li>\n      <li>Flunco (TH);</li>\n      <li>Fluxar (ID);</li>\n      <li>Fluzin (KR);</li>\n      <li>Fluzole (AU, LK);</li>\n      <li>Fluzoral (TH);</li>\n      <li>Forcan (IN, LV, VN);</li>\n      <li>Fukole (MY, PH);</li>\n      <li>Fumay (TW);</li>\n      <li>Funa (TH);</li>\n      <li>Funazol (KR);</li>\n      <li>Funex (CO);</li>\n      <li>Fungata (AT, DE);</li>\n      <li>Fungicon (ZW);</li>\n      <li>Fungostatin (GR);</li>\n      <li>Fungoz (ID);</li>\n      <li>Funzela (PH);</li>\n      <li>Funzol (AE, HR, JO, LB, QA, SA);</li>\n      <li>Fuzolan (ID);</li>\n      <li>Fuzolsel (VN);</li>\n      <li>Kyrin (TH);</li>\n      <li>Medoflucon (CN, SG);</li>\n      <li>Mikosyst (UA);</li>\n      <li>Mutum (AR, PE, VE);</li>\n      <li>Mycocyst (BM, BS, BZ, GY, JM, SR, TT);</li>\n      <li>Mycomox (LV);</li>\n      <li>Mycorest (SG);</li>\n      <li>Mycosyst (HU);</li>\n      <li>Mycozole (PH);</li>\n      <li>Neoconal (KR);</li>\n      <li>Nobzol-1 (CO);</li>\n      <li>Nobzol-2 (CO);</li>\n      <li>Odaft (MY, PH);</li>\n      <li>Omastin (SG);</li>\n      <li>Onecan (LK);</li>\n      <li>Oneflu (KR);</li>\n      <li>Oramax (AE, ET, KW, LB, QA, SA);</li>\n      <li>Oxifungol (MX);</li>\n      <li>Oxole (AU);</li>\n      <li>Sixanol (PY, UY);</li>\n      <li>Spirolac (PY);</li>\n      <li>Stabilanol (ET, IL);</li>\n      <li>Stalene (TH);</li>\n      <li>Syscan (ET, IN);</li>\n      <li>Tavor (EC);</li>\n      <li>Tinazole (KR);</li>\n      <li>Treflucan (AE, BH, CY, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Triflucan (FR, IL, TR);</li>\n      <li>Trigal (BD);</li>\n      <li>Uzol (TW);</li>\n      <li>Zemyc (ID);</li>\n      <li>Zoldicam (MX);</li>\n      <li>Zoleshot (PH);</li>\n      <li>Zolmed (VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aleck KA and Bartley DL, &ldquo;Multiple Malformation Syndrome Following Fluconazole Use in Pregnancy: Report of an Additional Patient,&rdquo; <i>Am J Med Genet</i>, 1997, 72(3):253-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9332650/pubmed\" target=\"_blank\" id=\"9332650\">9332650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alsaad AM, Kaplan YC, Koren G. Exposure to fluconazole and risk of congenital malformations in the offspring: A systematic review and meta-analysis. <i>Reprod Toxicol</i>. 2015;52:78-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/25724389/pubmed\" target=\"_blank\" id=\"25724389\">25724389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bean LM, Jackson JR, Dobak WJ, Beiswenger TR, Thorp JA. Intra-amniotic fluconazole therapy for Candida albicans intra-amniotic infection. <i>Obstet Gynecol</i>. 2013;121(2 Pt 2 Suppl 1):452-454.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23344406/pubmed\" target=\"_blank\" id=\"23344406\">23344406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bodley V, Powers D. Long-term treatment of a breastfeeding mother with fluconazole-resolved nipple pain caused by yeast: a case study. <i>J Hum Lact.</i>1997;13(4):307-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9429366/pubmed\" target=\"_blank\" id=\"9429366\">9429366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm</i>. 2013,70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brent NB. Thrush in the breastfeeding dyad: results of a survey on diagnosis and treatment. <i>Clin Pediatr (Phila)</i>. 2001;40(9):503-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/11583049/pubmed\" target=\"_blank\" id=\"11583049\">11583049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,&quot; <i>MMWR Recomm Rep</i>, 2009, 58(RR-11):1-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman SW, Dismukes WE, Proia LA. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2005;41:1217-1223.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chetwynd EM, Ives TJ, Payne PM, Edens-Bartholomew N. Fluconazole for postpartum candidal mastitis and infant thrush. <i>J Hum Lact. </i>2002;18(2):168-171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/15181494/pubmed\" target=\"_blank\" id=\"15181494\">15181494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Como JA and Dismukes WE, &quot;Oral Azole Drugs as Systemic Antifungal Therapy,&quot; <i>N Engl J Med</i>, 1993, 330(4):263-72.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents, &quot;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA),&quot; May 7, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Driessen M, Ellis JB, Cooper PA,et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. <i>Pediatr Infect Dis J</i>. 1996;15(12):1107-1112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/8970221/pubmed\" target=\"_blank\" id=\"8970221\">8970221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert. MedWatch. Fluconazole (Diflucan): Drug Safety Communication - FDA Evaluating Study Examining Use of Oral Fluconazole (Diflucan) in Pregnancy. Food and Drug Administration website. Available at <a href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm497656.htm\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm497656.htm</a>. April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Filioti J, Spiroglou K, Panteliadis CP, et al, &quot;Invasive Candidiasis in Pediatric Intensive Care Patients: Epidemiology, Risk Factors, Management, and Outcome,&quot;<i> Intensive Care Med</i>, 2007, 33(7):1272-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/17503015/pubmed\" target=\"_blank\" id=\"17503015\">17503015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Force RW, &ldquo;Fluconazole Concentrations in Breast Milk,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(3):235-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/7761190/pubmed\" target=\"_blank\" id=\"7761190\">7761190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. <i>Clin Infect Dis</i>. 2005;41(9):1217-1223.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goodman JL, Winston DJ, Greenfield RA, et al, &quot;A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow Transplantation,&quot; <i>N Engl J Med</i>, 1992, 326(13):845-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/1542320 /pubmed\" target=\"_blank\" id=\"1542320 \">1542320 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Healy CM and Baker CJ, &quot;Fluconazole Prophylaxis in the Neonatal Intensive Care Unit,&quot; <i>Pediatr Infect Dis J</i>, 2009, 28(1):49-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19106754/pubmed\" target=\"_blank\" id=\"19106754\">19106754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2017. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. September 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed October 8, 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howley MM, Carter TC, Browne ML, et al. Fluconazole use and birth defects in the National Birth Defects Prevention Study. <i>Am J Obstet Gynecol. </i>2016;214(5):657.e1-657.e9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/26640069/pubmed\" target=\"_blank\" id=\"26640069\">26640069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. <i>Pharmacotherapy. </i>1999;19(2):221-222.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/10030772/pubmed\" target=\"_blank\" id=\"10030772\">10030772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalish RB, Garry D, Figueroa R. Achalasia with Candida esophagitis during pregnancy. <i>Obstet Gynecol</i>. 1999;94(5 Pt 2):850.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/10546761/pubmed\" target=\"_blank\" id=\"10546761\">10546761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krcmery V Jr, Huttova M, Masar O. Teratogenicity of fluconazole .<i>Pediatr Infect Dis J</i>. 1996;15(9):841.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/8878238/pubmed\" target=\"_blank\" id=\"8878238\">8878238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee JW, Seibel NL, Amantea M, et al, &quot;Safety and Pharmacokinetics of Fluconazole in Children With Neoplastic Diseases,&quot; <i>J Pediatr</i>, 1992, 120(6):987-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/1593362/pubmed\" target=\"_blank\" id=\"1593362\">1593362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. <i>Birth Defects Res Part A Clin Mol Teratol</i>. 2005;73(11):919-923.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/16265639/pubmed\" target=\"_blank\" id=\"16265639\">16265639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mastroiacovo P, Mazzone T, Botto LD, et al, &ldquo;Prospective Assessment of Pregnancy Outcomes After First-Trimester Exposure to Fluconazole,&rdquo; <i>Am J Obstet Gynecol</i>, 1996, 175(6):1645-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/8987954/pubmed\" target=\"_blank\" id=\"8987954\">8987954</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. <i>N Engl J Med</i>. 2013;369(9):830-839.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23984730/pubmed\" target=\"_blank\" id=\"23984730\">23984730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molgaard-Nielsen D, Svanstrom H, Melbye M, Hviid A, Pasternak B. Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. <i>JAMA</i>. 2016;315(1):58-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/26746458/pubmed\" target=\"_blank\" id=\"26746458\">26746458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moncino MD and Gutman LT, &quot;Severe Systemic Cryptococcal Disease in a Child: Review of Prognostic Indicators Predicting Treatment Failure and an Approach to Maintenance Therapy With Oral Fluconazole,&quot; <i>Pediatr Infect Dis J</i>, 1990, 9(5):363-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/2352821/pubmed\" target=\"_blank\" id=\"2352821\">2352821</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moorhead AM, Amir LH, O'Brien PW, Wong S. A prospective study of fluconazole treatment for breast and nipple thrush. <i>Breastfeed Rev</i>. 2011;19(3):25-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/22263374/pubmed\" target=\"_blank\" id=\"22263374\">22263374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norgaard M, Pedersen L, Gislum M, et al. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. <i>J Antimicrob Chemother</i>. 2008;62(1):172-176.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/18400803/pubmed\" target=\"_blank\" id=\"18400803\">18400803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes D, et al, &quot;Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2009, 48(5):503-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19191635/pubmed\" target=\"_blank\" id=\"19191635\">19191635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span><span class=\"doi\">10.1093/cid/civ933</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010;50(3):291-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/20047480/pubmed\" target=\"_blank\" id=\"20047480\">20047480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Piper L, Smith PB, Hornik CP, et al, &quot;Fluconazole Loading Dose Pharmacokinetics and Safety in Infants,&quot; <i>Pediatr Infect Dis J</i>, 2011, 30(5):375-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/21085048/pubmed\" target=\"_blank\" id=\"21085048\">21085048</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA. Fluconazole-induced congenital anomalies in three infants. <i>Clin Infect Dis</i>. 1996;22(2):336-340.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/8838193/pubmed\" target=\"_blank\" id=\"8838193\">8838193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schilling CG, Seay RE, Larson TA, Meier KR. Excretion of fluconazole inhuman breast milk [abstract].<i>Pharmacotherapy</i>, 1993;13(3):287.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sorensen HT, Nielsen GL, Olesen C, et al, &ldquo;Risk of Malformations and Other Outcomes in Children Exposed to Fluconazole <i>in utero</i>,&rdquo; <i>Br J Clin Pharmacol</i>, 1999, 48(2):234-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/10417502/pubmed\" target=\"_blank\" id=\"10417502\">10417502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viscoli C, Castagnola E, Fioredda F, et al, &quot;Fluconazole in the Treatment of Candidiasis in Immunocompromised Children,&quot; <i>Antimicrob Agents Chemother</i>, 1991, 35(2):365-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/2024968/pubmed\" target=\"_blank\" id=\"2024968\">2024968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wade KC, Benjamin DK Jr, Kaufman DA, et al, &quot;Fluconazole Dosing for the Prevention or Treatment of Invasive Candidiasis in Young Infants,&quot; <i>Pediatr Infect Dis J</i>, 2009, 28(8):717-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19593252/pubmed\" target=\"_blank\" id=\"19593252\">19593252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wade KC, Wu D, Kaufman DA, et al, &quot;Population Pharmacokinetics of Fluconazole in Young Infants,&quot; <i>Antimicrob Agents Chemother</i>, 2008, 52(11):4043-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/18809946/pubmed\" target=\"_blank\" id=\"18809946\">18809946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al. Consensus guideline for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012. <i>Peritoneal Dialysis International</i>. 2012;32:s32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2007;45(7):807-825.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/17806045/pubmed\" target=\"_blank\" id=\"17806045\">17806045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiesinger EC, Mayerhofer S, Wenisch C, Breyer S, Graninger W. Fluconazole in Candida albicans sepsis during pregnancy: case report and review of the literature. <i>Infection. </i>1996;24(3):263-266.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/8811369/pubmed\" target=\"_blank\" id=\"8811369\">8811369</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaoutis T, &quot;Candidemia in Children,&quot; <i>Curr Med Res Opin</i>, 2010, 26(7):1761-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/20513207/pubmed\" target=\"_blank\" id=\"20513207\">20513207</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13303 Version 270.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F171677\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F171678\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047385\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442534\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047378\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F171652\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F171637\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047389\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132520\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F171672\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047388\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F171739\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F171736\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F171659\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F171641\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F171724\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F171646\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F171648\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F171662\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047384\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F171640\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F171658\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F13255706\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F171661\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F171665\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13303|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">Fluconazole: Drug information</a></li><li><a href=\"topic.htm?path=fluconazole-patient-drug-information\" class=\"drug drug_patient\">Fluconazole: Patient drug information</a></li></ul></div></div>","javascript":null}